Guselkumab for the treatment of adults with moderate to severe plaque psoriasis

Research output: Contribution to journalArticleResearch

4 Citations (Scopus)

Abstract

© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Guselkumab is a subcutaneously administered monoclonal antibody that targets the IL-23p19 cytokine subunit and has been approved by the US FDA and the EMA for the treatment of moderate-to-severe psoriasis in adult patients. Areas covered: This review outlines the pharmacologic properties, efficacy and safety of guselkumab for the treatment of moderate-to-severe plaque psoriasis in adults. Expert opinion: In clinical trials, guselkumab markedly improved disease, regardless of topographical locations and patient subpopulations, with corresponding improvements in quality of life measures, and was generally well tolerated. Guselkumab has been shown to be more effective than adalimumab in phase III pivotal trials (VOYAGE 1 and VOYAGE 2) at both week 16 and week 24 for PASI75, PASI90, PASI100 and IGA(0/1); the corresponding PASI 90 response rates at week 16 were 73.3% vs 49.7% in VOYAGE 1 and 70.0% vs 46.8% in VOYAGE 2 (P < 0.001 in both). Guselkumab has been shown to be superior to secukinumab in PASI90 response rate at week 48 in a head-to-head trial (ECLIPSE); it is also successful in treating patients with incomplete responses to adalimumab (VOYAGE 2) and ustekinumab (NAVIGATE). Guselkumab may be effective in treating psoriatic arthritis, with several phase III trials ongoing.
Original languageEnglish
Pages (from-to)589-597
JournalExpert Review of Clinical Immunology
Volume15
DOIs
Publication statusPublished - 3 Jun 2019

Keywords

  • guselkumab
  • IL-17A
  • IL-23
  • p19
  • Psoriasis

Fingerprint Dive into the research topics of 'Guselkumab for the treatment of adults with moderate to severe plaque psoriasis'. Together they form a unique fingerprint.

Cite this